Executive Director, Government Affairs, Europe

About the role

Revolution Medicines is seeking an Executive Director, Government Affairs, Europe to build and lead the company's government affairs strategy across Europe as the organization prepares for potential oncology launches and a growing regional presence.This leader will be responsible for shaping and executing European government affairs priorities that support patient access, launch readiness, and long-term value for RevMed's innovative oncology portfolio. The role will focus on the evolving EU and country-level policy environment, including oncology access, pricing and reimbursement, HTA, innovation incentives, regulatory and legislative developments, and health system sustainability. The Executive Director will be a key member of the Market Access leadership team to ensure that policy insights and external engagement are directly connected to access strategy, HTA planning, reimbursement, country launch sequencing, and stakeholder engagement. The role will partner closely with Corporate Communications / Corporate Affairs, Regulatory, Medical Affairs, Commercial, Legal, Compliance, Patient Advocacy, and global colleagues to ensure consistent and coordinated engagement across the company. This is a highly strategic, externally facing role for a senior leader who can establish the function, advise the business, represent RevMed credibly with policy stakeholders and industry associations, and translate the European policy landscape into practical business implications and opportunities.

Responsibilities

• Develop and lead the European government affairs strategy in alignment with Market Access, commercial readiness, global policy priorities, and RevMed's mission to serve patients with RAS-addicted cancers.
• Monitor, analyze, and communicate EU and country-level policy developments that may affect oncology innovation, HTA, pricing and reimbursement, patient access, clinical research, diagnostics, data, and launch execution.
• Provide strategic counsel to European and global leadership on policy risks, opportunities, and implications for launch planning, value strategy, access sequencing, and stakeholder engagement.
• Serve as the policy lead within the Market Access team, ensuring European policy perspectives are embedded into HTA readiness, payer engagement planning, value communication, reimbursement strategy, and country-level access plans.
• Work closely with Corporate Communications / Corporate Affairs to align policy positions, external messaging, reputation considerations, and issues management across European stakeholders.
• Represent RevMed in relevant European and national trade associations, policy forums, and coalitions, and ensure internal teams are informed of key outputs and opportunities for engagement.
• Partner with Legal and Compliance to ensure all government affairs activities comply with applicable rules, transparency requirements, codes of practice, and company standards.
• Establish operating processes, governance, and internal communication mechanisms for the European government affairs function, including policy tracking, stakeholder mapping, briefing materials, and leadership updates.
• Contribute to cross-functional launch readiness and scenario planning by anticipating policy and access barriers and identifying opportunities to support timely and sustainable patient access.
• Partner with global, regional, and affiliate RevMed leadership to develop aligned access plans and to lead a policy and access community, enabling the sharing of best practices, experiences, and priorities across markets.
• Required Skills, Experience and Education:
• Bachelor's degree required; advanced degree in public policy, law, political science, health economics, life sciences, public health, or a related field preferred.
• 12+ years of progressive experience in government affairs, public policy, market access, healthcare policy,

Benefits

Additional Information

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at revolutionmedicines? Share your experience